SOL-GEL TECHN. IS-10 (4SG) - Total Liabilities
Based on the latest financial reports, SOL-GEL TECHN. IS-10 (4SG) has total liabilities worth €7.11 Million EUR (≈ $8.31 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is SOL-GEL TECHN. IS-10 growing its equity to track the company's year-over-year net asset growth rate.
SOL-GEL TECHN. IS-10 - Total Liabilities Trend (2021–2025)
This chart illustrates how SOL-GEL TECHN. IS-10's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of SOL-GEL TECHN. IS-10 to measure how efficiently the company converts operating cash flow to free cash.
SOL-GEL TECHN. IS-10 Competitors by Total Liabilities
The table below lists competitors of SOL-GEL TECHN. IS-10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hi-Tech Pipes Limited
NSE:HITECH
|
India | Rs6.90 Billion |
|
Copley Acquisition Corp
NYSE:COPL
|
USA | $721.22K |
|
Gulf Island Fabrication Inc
NASDAQ:GIFI
|
USA | $52.42 Million |
|
Hong Leong Capital Bhd
KLSE:5274
|
Malaysia | RM3.85 Billion |
|
Minerva Neurosciences Inc
NASDAQ:NERV
|
USA | $348.04 Million |
|
Hong Pu Real Estate Development Co Ltd
TW:2536
|
Taiwan | NT$27.64 Billion |
|
Can2 Termik AS
IS:CANTE
|
Turkey | TL4.08 Billion |
|
Millennial Potash Corp.
V:MLP
|
Canada | CA$1.39 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down SOL-GEL TECHN. IS-10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SOL-GEL TECHN. IS-10 stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SOL-GEL TECHN. IS-10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SOL-GEL TECHN. IS-10 (2021–2025)
The table below shows the annual total liabilities of SOL-GEL TECHN. IS-10 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €7.11 Million ≈ $8.31 Million |
+1.57% |
| 2024-12-31 | €7.00 Million ≈ $8.18 Million |
+5.31% |
| 2023-12-31 | €6.64 Million ≈ $7.77 Million |
+50.46% |
| 2022-12-31 | €4.42 Million ≈ $5.16 Million |
-67.52% |
| 2021-12-31 | €13.60 Million ≈ $15.89 Million |
-- |
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more